The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
The grant is designated for the research and development of Pyronaridine
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
e brings over 27+ years of rich pharmaceutical experience
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples
Subscribe To Our Newsletter & Stay Updated
